Double maintains 3 strategies that include PCRX - Pacira Biosciences, Inc.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PUBM | 47.93% | $663.46M | -32.43% | 0.00% |
WBTN | 45.19% | $1.28B | -50.77% | 0.00% |
FIVN | 44.10% | $2.12B | -33.22% | 0.00% |
MITK | 42.30% | $450.63M | -13.17% | 0.00% |
AVD | 42.07% | $137.96M | -53.51% | 0.00% |
NATR | 34.19% | $288.95M | +4.06% | 0.00% |
MTUS | 31.16% | $686.66M | -20.91% | 0.00% |
SEE | 28.10% | $4.81B | -7.39% | 2.44% |
JYNT | 27.88% | $181.19M | -13.20% | 0.00% |
GRVY | 27.81% | $443.86M | -20.44% | 0.00% |
TPST | 27.49% | $30.08M | -73.91% | 0.00% |
AQN | 27.05% | $4.63B | -6.40% | 4.49% |
FIGS | 27.04% | $1.00B | +11.19% | 0.00% |
PRO | 26.88% | $778.56M | -35.51% | 0.00% |
ALKS | 26.84% | $5.02B | +30.67% | 0.00% |
MTW | 26.33% | $474.59M | +21.62% | 0.00% |
EB | 25.91% | $255.07M | -41.28% | 0.00% |
RWAY | 25.78% | $408.95M | -5.91% | 13.33% |
CDXS | 24.74% | $257.65M | -4.60% | 0.00% |
RPAY | 24.52% | $441.64M | -47.84% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CAH | -0.01% | $38.71B | +71.68% | 1.26% |
TEF | 0.02% | $29.35B | +18.72% | 6.32% |
GPRK | 0.03% | $371.48M | -33.39% | 8.12% |
PBPB | 0.05% | $381.68M | +71.88% | 0.00% |
DOUG | 0.07% | $222.73M | +105.74% | 0.00% |
CSAN | -0.11% | $2.18B | -55.39% | 0.00% |
LAUR | 0.12% | $3.55B | +58.40% | 0.00% |
FROG | -0.12% | $4.65B | +12.45% | 0.00% |
MNDY | -0.12% | $15.29B | +30.20% | 0.00% |
SOLV | 0.12% | $13.13B | +53.73% | 0.00% |
APEI | -0.14% | $559.05M | +73.13% | 0.00% |
RCKY | -0.14% | $181.75M | -28.16% | 2.57% |
STTK | -0.14% | $37.09M | -80.88% | 0.00% |
IMMP | 0.15% | $239.50M | -18.41% | 0.00% |
TXMD | 0.15% | $13.89M | -32.58% | 0.00% |
CATO | 0.16% | $60.00M | -43.60% | 5.59% |
VRCA | 0.16% | $80.70M | -89.71% | 0.00% |
ABEV | 0.16% | $36.61B | +9.35% | 5.65% |
BW | -0.18% | $103.32M | -48.78% | 0.00% |
TRUG | -0.18% | $5.41M | -89.51% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DOCS | -38.23% | $11.28B | +121.78% | 0.00% |
QNTM | -34.61% | $51.29M | +99.37% | 0.00% |
TBRG | -30.73% | $344.94M | +116.20% | 0.00% |
G | -28.18% | $7.92B | +42.14% | 1.44% |
ADMA | -27.09% | $4.41B | +50.04% | 0.00% |
CARG | -25.48% | $3.43B | +36.05% | 0.00% |
SG | -23.27% | $1.61B | -44.78% | 0.00% |
PRA | -20.01% | $1.22B | +106.78% | 0.00% |
HRTG | -19.39% | $661.40M | +211.08% | 0.00% |
VHC | -18.80% | $69.05M | +176.10% | 0.00% |
EVH | -17.71% | $1.32B | -42.76% | 0.00% |
RCEL | -15.28% | $147.57M | -32.42% | 0.00% |
CDLX | -15.08% | $93.98M | -78.04% | 0.00% |
SBS | -14.94% | $13.75B | +30.48% | 3.28% |
TGS | -14.28% | $1.83B | +40.75% | 0.00% |
IAG | -14.18% | $4.00B | +64.30% | 0.00% |
VIRT | -13.85% | $3.78B | +96.56% | 2.19% |
SLVM | -13.00% | $2.16B | -21.43% | 3.44% |
AGRO | -12.67% | $913.94M | -7.96% | 3.83% |
PAY | -12.02% | $3.67B | +51.19% | 0.00% |
Current Value
$23.681 Year Return
Current Value
$23.681 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
UCON | <0.01% | $2.95B | 0.86% |
SPBO | 0.01% | $1.62B | 0.03% |
PFFR | 0.06% | $94.76M | 0.45% |
UDN | 0.07% | $147.46M | 0.78% |
SCHO | -0.13% | $10.98B | 0.03% |
IGEB | -0.17% | $1.26B | 0.18% |
FXE | -0.26% | $588.06M | 0.4% |
VTC | -0.32% | $1.19B | 0.03% |
UNG | 0.33% | $375.27M | 1.06% |
PULS | -0.35% | $11.74B | 0.15% |
IBTH | 0.36% | $1.62B | 0.07% |
FLCO | 0.37% | $597.52M | 0.35% |
UUP | -0.41% | $196.45M | 0.77% |
IBDV | -0.43% | $1.90B | 0.1% |
MSOS | 0.43% | $343.11M | 0.77% |
CGMS | -0.46% | $2.88B | 0.39% |
UGA | 0.50% | $76.33M | 0.97% |
BSCU | 0.51% | $1.65B | 0.1% |
FLBR | 0.53% | $213.13M | 0.19% |
USIG | -0.67% | $14.09B | 0.04% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XPH | 25.83% | $150.58M | 0.35% |
PINK | 20.66% | $130.30M | 0.5% |
FBT | 19.35% | $1.02B | 0.54% |
PBE | 19.35% | $226.91M | 0.58% |
RZV | 18.78% | $213.28M | 0.35% |
IBB | 17.85% | $5.37B | 0.45% |
IWC | 17.85% | $840.86M | 0.6% |
BSJP | 17.76% | $850.15M | 0.43% |
YYY | 17.72% | $580.28M | 3.25% |
FTSL | 17.59% | $2.39B | 0.87% |
CGW | 17.55% | $984.15M | 0.59% |
BBH | 17.53% | $339.54M | 0.35% |
BSVO | 17.49% | $1.55B | 0.47% |
VIOV | 17.46% | $1.31B | 0.1% |
RDTE | 17.42% | $139.04M | 0.97% |
IWN | 17.42% | $11.34B | 0.24% |
CALF | 17.41% | $4.27B | 0.59% |
SMDV | 17.01% | $669.78M | 0.4% |
GSSC | 16.96% | $591.16M | 0.2% |
RWJ | 16.90% | $1.56B | 0.39% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
MMIN | -18.18% | $322.53M | 0.3% |
SHYD | -17.55% | $331.91M | 0.35% |
BILZ | -17.36% | $851.85M | 0.14% |
BSMW | -17.27% | $107.49M | 0.18% |
SMMU | -17.11% | $896.32M | 0.35% |
TAXF | -15.23% | $477.91M | 0.29% |
MUST | -14.69% | $439.44M | 0.23% |
TFLO | -14.10% | $6.74B | 0.15% |
PZA | -13.93% | $2.83B | 0.28% |
SHM | -13.47% | $3.41B | 0.2% |
CMF | -13.14% | $3.50B | 0.08% |
SCMB | -12.80% | $2.10B | 0.03% |
PWZ | -12.75% | $776.05M | 0.28% |
ITM | -12.21% | $1.87B | 0.18% |
TFI | -12.11% | $3.21B | 0.23% |
FLMI | -12.11% | $735.37M | 0.3% |
VTEB | -12.03% | $37.74B | 0.03% |
CGSM | -12.02% | $716.74M | 0.25% |
JMUB | -11.99% | $3.06B | 0.18% |
FMB | -11.62% | $1.89B | 0.65% |
Yahoo
Pacira BioSciences Inc. (NASDAQ:PCRX) is one of the most undervalued small-cap stocks to buy according to analysts. On June 11, Pacira BioSciences announced new long-term follow-up data from its Phase 1 clinical trial of PCRX-201 (enekinragene inzadenovec), which is an investigational gene therapy for osteoarthritis of the knee. The results were presented at the 2025 […]
Finnhub
Pacira BioSciences Inc: Pacira BioSciences Inc - reduction impacts 71 employees, 8% of workforce - SEC FILING Pacira BioSciences Inc - estimates $2.4-$2.8 million pre-tax charges for termination...
Yahoo
BRISBANE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on July 2, 2025 to seven new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5
Finnhub
Pacira BioSciences, Inc. dropped from Russell 2000 Value-Defensive Index...
Finnhub
Pacira BioSciences, Inc. dropped from Russell 2000 Growth-Defensive Index...
Finnhub
Pacira BioSciences, Inc. dropped from Russell 2000 Defensive Index...